TRV
CARM

Third Rock Ventures’s Carisma Therapeutics CARM Stock Holding History

Third Rock Ventures’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$11.7M Hold
242,080
– – 1.09% 4
2015
Q2 		$13.7M Hold
242,080
– – 1.42% 4
2015
Q1 		$43.2M Hold
242,080
– – 4.61% 4
2014
Q4 		$57.5M Hold
242,080
– – 4.7% 6
2014
Q3 		$53.9M Hold
242,080
– – 6.29% 5
2014
Q2 		$63.8M Hold
242,080
– – 13.63% 4
2014
Q1 		$78.6M Buy
+242,080
New +$72.5M 13.93% 3

Other funds holding CARM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Third Rock Ventures's CARM Position: Q3 2015 in Review

Third Rock Ventures held its Carisma Therapeutics (CARM) position steady in Q3 2015 at 242,080 shares worth $11.7M. The position accounts for 1.09% of the portfolio, ranked #4.

Third Rock Ventures first reported a position in CARM in Q1 2014 and has held it in 7 quarters since. The position peaked at $78.6M in Q1 2014. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

  • Third Rock Ventures held 242,080 shares of Carisma Therapeutics worth $11.7M as of Q3 2015.
  • Third Rock Ventures left its Carisma Therapeutics share count unchanged in Q3 2015.
  • Carisma Therapeutics made up 1.09% of Third Rock Ventures's portfolio in Q3 2015, its #4 holding.
  • Third Rock Ventures first reported a position in Carisma Therapeutics in Q1 2014 and has held it in 7 quarters since.
  • Third Rock Ventures's Carisma Therapeutics position peaked at $78.6M in Q1 2014.
  • 30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on Third Rock Ventures's 13F filing for Q3 2015, filed 3 Nov 2015.